3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
31
Recruiting
26
Unknown
20
Not yet recruiting
6
Active not recruiting
4
Withdrawn
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
14
Thoracic
13
Breast
11
Other hematologic neoplasm
7
Genitourinary
5
Sarcoma
4
Lymphoid
4
Head & Neck
3
Dermatologic
3
CNS
3
Tumor-Agnostic
2
Other solid neoplasm
1
Myeloid
1
Gynecologic
1
Classical hematology
1
Conditions
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
Paclitaxel
69
Carboplatin
66
Cisplatin
36
pembrolizumab
34
Gemcitabine
24
liposomal doxorubicin
23
Cyclophosphamide
23
Topotecan
22
Bevacizumab
20
Taxes
14
Docetaxel
13
niraparib
12
Nivolumab
12
olaparib
10
fludarabine
10
Doxorubicin
9
Surveys and Questionnaires
8
Radiotherapy
8
Oxaliplatin
8
aldesleukin
7
Filgrastim
7
rucaparib
6
oregovomab
6
fludarabine phosphate
6
durvalumab
6
avelumab
6
Interleukin-2
6
Hyperthermic Intraperitoneal Chemotherapy
6
Fluorodeoxyglucose F18
6
Cytoreduction Surgical Procedures
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Drug Therapy
×
Gynecologic
×
Clear all
NCT03642132
2023-04-06
JAVELIN OVARIAN PARP100
Pfizer
Phase 3
Terminated
79 enrolled
18 charts